BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VMT Scientific Inc. (VMTF.PK) Announces Unilateral Development


11/28/2005 11:05:21 AM

LAS VEGAS, Nov. 28 /PRNewswire-FirstCall/ -- VMT Scientific Inc. announces that's its globally patented breakthrough technology known as the VasCir (TM) system has now begun development of it's hand, finger and limb units, as well as the feet. After fielding calls from desperate individuals facing amputations, their Doctors, requesting to be part of the trials as to help speed testing and Medical Centers worldwide. VMT Scientific Inc has moved its scheduled monolithic development into a unilateral phase, where all products will be developed along the same lines. It's a FACT that in 2003, it was estimated that over one half billion people worldwide suffer from some form of Diabetic or Pre-Diabetic condition, that will effect the normal blood flow to their extremities and compromise their health. Out of that half billion people, approx 40% of those will lead to amputations.

The VasCir (TM) System is predicted to reduce the number of PVD related amputations by 50% or more. VMT Scientific Inc's CTO states that there is no known technology that can establish blood flow to the extremities the same way the VasCir (TM) system can. Documented preliminary tests indicated that as much as a 300% increase in arterial blood flow to the treated limb in as little as 15 minutes. This life and limb saving arterial blood carries with it rich oxygen and nutrients that are necessary for proper limb health.

The World's demand for the VasCir (TM) system is staggering! Based on USA estimates, every 8 minutes an individual's foot is amputated and a staggering 2 million toes and fingers are amputated annually due to the effects of PVD!

The potential market for VMT Scientific Inc's patented technology is in the millions of units sold annually. The VasCir (TM) system goal is to earn FDA approval and to qualify as a Medicare reimbursable. VMT Scientific Inc. is poised for a healthy financial future as well as saving lives and limbs. If these projected estimates hold true, everybody wins, the patients, the Doctors, and the Stockholders.

Please visit VMT Scientific, Inc.'s Web site for more information: http://www.vmtf.org

This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. Technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientifics' future access to capital to sustain operations, achieve profitability, to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property and or continue as a going concern. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations.

VMT Scientific Inc.

CONTACT: Catherine S. Ratelle, Director of Operations, VMT Scientific,Inc., +1-702-990-3477



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES